SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

KIMIA BIOSCIENCES

BSE: 530313 29 Jun 2025
Healthcare
₹ 50.5
KIMIA BIOSCIENCES LIMITED specializes in Pharmaceuticals within the Healthcare sector.

KIMIA BIOSCIENCES - Share Price & Details

Market Cap
₹290.0
High /Low
61.2 / 35.1
Stock P/E
30.1
Book Value
₹1.68
Dividend Yield
0.0
ROCE
41.3
ROE
₹2,912
Face Value
1.0
PEG Ratio
0.64
EVEBITDA
₹15.0
Debt
33.9
CMP / FCF
43.1
Debt to equity
₹4.27
NP Ann
9.61
High price all time
76.5
Piotroski score
₹7.0
Graham Number
8.76
No. Eq. Shares
4.73
Net CF
₹0.06
Net profit
9.61
Price to book value
36.4
Interest Coverage
₹3.99
Low price all time
5.0
Industry PE
32.7
Reserves
₹3.22
Free Cash Flow
₹16.7

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
KIMIA BIOSCIENCES LIMITEDNANANANA290.030.1
GENNEX LABORATORIES LTD.NANANANA28517.7
Nureca Limited337.4820.72317.52.07278

Peer Comparison Chart


About KIMIA BIOSCIENCES

KIMIA BIOSCIENCES LIMITED, with Security Code 530313, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Sensex rises! These stocks gained over 10% on BSE

(27 May 2025)
In the Nifty 50 index, 38 stocks ended in the green, while 12 stocks closed in the red in today's trade.
Read more →

Kimia Bio Standalone March 2025 Net Sales at Rs 38.24 crore, up 26.21% Y-o-Y

(27 May 2025)
Net Sales at Rs 38.24 crore in March 2025 up 26.21% from Rs. 30.30 crore in March 2024. Story continues below Advertisement.
Read more →

Q4 results: Aurobindo Pharma, Shilpa Medicare, Nazara Technologies to announce March quarter numbers on May 26; check details

(26 May 2025)
Auropbindo Pharma, Shilpa Medicare, Yathath Hospital, Nazara Technologies, Olectra Greentech, Orchid Pharma, RateGain Travel technologies...
Read more →

Kimia Biosciences Faces Increased Bearish Outlook Amid High Debt Concerns

(23 May 2025)
Kimia Biosciences has experienced a recent evaluation adjustment, reflecting a shift in its technical outlook. Despite a positive Q3 FY24-25 financial...
Read more →

Kimia Biosciences Adjusts Evaluation Amid Strong Profit Growth and Debt Concerns

(23 May 2025)
Kimia Biosciences has recently experienced an evaluation adjustment amid mixed financial indicators. The company reported a significant increase in net...
Read more →

Kimia Biosciences Says Rakesh Chetani Resigns As CFO

(23 Apr 2025)
Kimia Biosciences Limited is an India-based company, which is engaged in the business of pharmaceutical products. The Company provides its...
Read more →